vincristine + methotrexate + mercaptopurine + prednisone

The combination of vincristine, methotrexate, mercaptopurine, and prednisone, commonly referred to as the **VAMP** regimen, is a low-intensity chemotherapy protocol developed and evaluated by **St. Jude Children's Research Hospital**. It is primarily utilized as a risk-adapted therapy for pediatric patients with previously untreated **Hodgkin lymphoma**. The regimen is designed to maintain high cure rates while significantly reducing the long-term toxicities and side effects associated with more intensive chemotherapy or high-dose radiation therapy. In the St. Jude protocol, VAMP is often used in patients who achieve a rapid complete response to initial treatment, potentially allowing them to avoid involved-field radiotherapy. The regimen's components include vincristine (a microtubule inhibitor), methotrexate (a folate antagonist), mercaptopurine (a purine antimetabolite), and prednisone (a corticosteroid).

Other names

VAMP regimenVAMP protocolVAMP chemotherapy